SPRED2 Inhibitors
SPRED2 inhibitors belong to a specific chemical class designed to modulate the activity of the Sprouty-related, EVH1 domain-containing protein 2 (SPRED2). SPRED2 is a crucial component of the mitogen-activated protein kinase (MAPK) signaling pathway, playing a pivotal role in regulating cellular responses to extracellular stimuli. The MAPK pathway is integral to various cellular processes such as proliferation, differentiation, and survival. SPRED2, by virtue of its inhibitory function, acts as a negative regulator in this cascade, exerting control over the intensity and duration of MAPK signaling.
SPRED2 inhibitors are meticulously designed compounds that interfere with the normal functioning of SPRED2. By targeting SPRED2, these inhibitors aim to modulate the intricate balance of signaling events, leading to downstream effects on cellular behavior. The development of SPRED2 inhibitors involves a deep understanding of the structural and biochemical properties of SPRED2, allowing for the rational design of molecules capable of binding to and modulating its activity. The ultimate goal of these inhibitors is to influence the MAPK pathway in a controlled manner, offering insights into the underlying molecular mechanisms governing cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a selective inhibitor of MEK1/2 in the Ras/MAPK pathway. Inhibiting these kinases downstream of SPRED2 can abrogate the effects of SPRED2 dysregulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that targets the MAPK/ERK pathway downstream of SPRED2, potentially mitigating the effects of SPRED2 deregulation. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib targets MEK1 and MEK2 in the MAPK/ERK pathway, potentially impacting the function of SPRED2. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Binimetinib is a selective inhibitor of MEK1/2, which act downstream of SPRED2. Inhibiting MEK1/2 may indirectly affect SPRED2 activity. | ||||||
AZD8330 | 869357-68-6 | sc-364425 sc-364425A | 5 mg 10 mg | $255.00 $450.00 | ||
AZD8330 is a MEK1/2 inhibitor that can indirectly affect SPRED2's function through the Ras/MAPK pathway. | ||||||
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $245.00 $428.00 | 1 | |
BAY 869766 (Refametinib) is a potent inhibitor of MEK, and can indirectly influence SPRED2 activity by targeting the Ras/MAPK pathway. | ||||||
PD 184,352 | 212631-79-3 | sc-202759 sc-202759A | 1 mg 5 mg | $40.00 $260.00 | 34 | |
PD 184,352 is a selective inhibitor of MEK1/2, which are downstream of SPRED2. Inhibiting these kinases can indirectly influence SPRED2's role. | ||||||